Literature DB >> 17218060

Unilateral 6-hydroxydopamine lesion of dopamine neurons and subchronic L-DOPA administration in the adult rat alters the expression of the vesicular GABA transporter in different subsets of striatal neurons and in the substantia nigra, pars reticulata.

H Wang1, J Katz, P Dagostino, J-J Soghomonian.   

Abstract

The loss of dopamine neurons combined or not with the subsequent administration of L-DOPA in patients with Parkinson's disease or in experimental models of the disease results in altered GABAergic signaling throughout the basal ganglia, including the striatum and the substantia nigra, pars reticulata. However, the molecular mechanisms involved in altered GABA neurotransmission remain poorly understood. In order to be released from synaptic vesicles, newly synthesized GABA is transported from the cytosol into synaptic vesicles by a vesicular GABA transporter. The objective of this study was to examine the hypothesis that expression of the vesicular GABA transporter (vGAT) is altered in the unilateral 6-hydroxydopamine model of Parkinson's disease. Our results provide evidence that a unilateral 6-hydroxydopamine lesion results in increased and decreased vGAT mRNA levels in striatopallidal and striatonigral neurons, respectively. These two subsets of neurons were identified by the co-expression or lack of co-expression of preproenkephalin, a marker of striatopallidal neurons, using double-labeling in situ hybridization histochemistry. Such changes occurred in the striatum ipsilateral to the 6-hydroxydopamine lesion and were paralleled by decreased vGAT protein levels in the substantia nigra, pars reticulate (SNr). On the other hand, the subchronic systemic administration of L-DOPA increased vGAT mRNA levels in preproenkephalin-negative neurons on the side ipsilateral and, to a lesser extent, the side contralateral to the 6-hydroxydopamine lesion. Systemic L-DOPA also increased vGAT protein levels in the ipsi- and contralateral SNr. As a whole, the results provide original evidence that vGAT expression is altered in the 6-hydroxydopamine model of Parkinson's disease. They also suggest that the behavioral effects induced by a subchronic administration of L-DOPA to 6-hydroxydopamine-lesioned rats involve an increase in the vesicular release of GABA by striatonigral neurons.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17218060      PMCID: PMC1894759          DOI: 10.1016/j.neuroscience.2006.12.001

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  45 in total

1.  Parallel increases in striatal glutamic acid decarboxylase activity and mRNA levels in rats with lesions of the nigrostriatal pathway.

Authors:  J Segovia; N J Tillakaratne; K Whelan; A J Tobin; K Gale
Journal:  Brain Res       Date:  1990-10-08       Impact factor: 3.252

2.  Comparative distribution of messenger RNAs encoding glutamic acid decarboxylases (Mr 65,000 and Mr 67,000) in the basal ganglia of the rat.

Authors:  M Mercugliano; J J Soghomonian; Y Qin; H Q Nguyen; S Feldblum; M G Erlander; A J Tobin; M F Chesselet
Journal:  J Comp Neurol       Date:  1992-04-15       Impact factor: 3.215

3.  Chronic continuous and intermittent L-3,4-dihydroxyphenylalanine treatments differentially affect basal ganglia function in 6-hydroxydopamine lesioned rats--an autoradiographic study using [3H]flunitrazepam.

Authors:  K K Gnanalingham; R G Robertson
Journal:  Neuroscience       Date:  1993-12       Impact factor: 3.590

4.  Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats.

Authors:  E D Abercrombie; A E Bonatz; M J Zigmond
Journal:  Brain Res       Date:  1990-08-13       Impact factor: 3.252

5.  Effects of nigrostriatal lesions on the levels of messenger RNAs encoding two isoforms of glutamate decarboxylase in the globus pallidus and entopeduncular nucleus of the rat.

Authors:  J J Soghomonian; M F Chesselet
Journal:  Synapse       Date:  1992-06       Impact factor: 2.562

6.  D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.

Authors:  C R Gerfen; T M Engber; L C Mahan; Z Susel; T N Chase; F J Monsma; D R Sibley
Journal:  Science       Date:  1990-12-07       Impact factor: 47.728

7.  The striatonigral dynorphin pathway of the rat studied with in vivo microdialysis--II. Effects of dopamine D1 and D2 receptor agonists.

Authors:  Z B You; M Herrera-Marschitz; I Nylander; M Goiny; W T O'Connor; U Ungerstedt; L Terenius
Journal:  Neuroscience       Date:  1994-11       Impact factor: 3.590

8.  Rat brain preproenkephalin mRNA. cDNA cloning, primary structure, and distribution in the central nervous system.

Authors:  K Yoshikawa; C Williams; S L Sabol
Journal:  J Biol Chem       Date:  1984-11-25       Impact factor: 5.157

9.  Messenger RNAs encoding glutamate-decarboxylases are differentially affected by nigrostriatal lesions in subpopulations of striatal neurons.

Authors:  J J Soghomonian; C Gonzales; M F Chesselet
Journal:  Brain Res       Date:  1992-03-27       Impact factor: 3.252

10.  Gamma-aminobutyric acid and benzodiazepine receptor changes induced by unilateral 6-hydroxydopamine lesions of the medial forebrain bundle.

Authors:  H S Pan; J B Penney; A B Young
Journal:  J Neurochem       Date:  1985-11       Impact factor: 5.372

View more
  7 in total

Review 1.  The significance of neuronal lateralisation in Parkinson's disease.

Authors:  P Riederer; J Sian-Hülsmann
Journal:  J Neural Transm (Vienna)       Date:  2012-02-26       Impact factor: 3.575

2.  Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats.

Authors:  Kristin B Dupre; Corinne Y Ostock; Jessica A George; Karen L Eskow Jaunarajs; Cara M Hueston; Christopher Bishop
Journal:  ACS Chem Neurosci       Date:  2013-04-01       Impact factor: 4.418

Review 3.  Target identification for CNS diseases by transcriptional profiling.

Authors:  C Anthony Altar; Marquis P Vawter; Stephen D Ginsberg
Journal:  Neuropsychopharmacology       Date:  2008-10-15       Impact factor: 7.853

4.  Time-course of SKF-81297-induced increase in glutamic acid decarboxylase 65 and 67 mRNA levels in striatonigral neurons and decrease in GABA(A) receptor alpha1 subunit mRNA levels in the substantia nigra, pars reticulata, in adult rats with a unilateral 6-hydroxydopamine lesion.

Authors:  N Yamamoto; J-J Soghomonian
Journal:  Neuroscience       Date:  2008-04-16       Impact factor: 3.590

5.  Neuroprotective changes in degeneration-related gene expression in the substantia nigra following acupuncture in an MPTP mouse model of Parkinsonism: Microarray analysis.

Authors:  Sujung Yeo; Keon Sang An; Yeon-Mi Hong; Yeong-Gon Choi; Bruce Rosen; Sung-Hoon Kim; Sabina Lim
Journal:  Genet Mol Biol       Date:  2014-03-17       Impact factor: 1.771

Review 6.  Convergent evidence for abnormal striatal synaptic plasticity in dystonia.

Authors:  David A Peterson; Terrence J Sejnowski; Howard Poizner
Journal:  Neurobiol Dis       Date:  2009-12-18       Impact factor: 5.996

7.  Non-dopaminergic Alterations in Depression-Like FSL Rats in Experimental Parkinsonism and L-DOPA Responses.

Authors:  Nicoletta Schintu; Xiaoqun Zhang; Nikolas Stroth; Aleksander A Mathé; Per E Andrén; Per Svenningsson
Journal:  Front Pharmacol       Date:  2020-03-20       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.